Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SymBio PharmaceuticalsTSE:4582 35 PB Ratio is 21.80 as of Jul. 14, 2026, which is 644% above its 10-year median of 2.93. GuruFocus rates TSE:4582 with a GF Score™ of 35/100 and a GF Value™ of 円60.86 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 921 Drug Manufacturers companies, SymBio Pharmaceuticals ranks worse than 97.61% on this metric.
SymBio Pharmaceuticals Ltd stock PB Ratio (=22.11) is close to 10-year high of 22.11.
The historical rank and industry rank for SymBio Pharmaceuticals's PB Ratio or its related term are showing as below:
TSE:4582'
s PB Ratio Range Over the Past 10 Years
Min: 0.96 Med: 2.93 Max: 22.11
Current: 21.8
During the past 13 years, SymBio Pharmaceuticals's highest PB Ratio was 22.11. The lowest was 0.96. And the median was 2.93.
TSE:4582's PB Ratio is ranked worse than 97.61% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.9
vs TSE:4582: 21.80
During the past 12 months, SymBio Pharmaceuticals's average Book Value Per Share Growth Rate was -76.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -53.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -26.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -19.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of SymBio Pharmaceuticals was 38.50% per year. The lowest was -53.70% per year. And the median was -18.90% per year.
Back to Basics: PB Ratio
SymBio Pharmaceuticals (TSE:4582) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, SymBio Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SymBio Pharmaceuticals PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SymBio Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where SymBio Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
SymBio Pharmaceuticals (TSE:4582) has a PB Ratio of 21.80 as of Jul. 14, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on SymBio Pharmaceuticals and its competitors. This is 644% above median its historical median of 2.93. Over the past decade, SymBio Pharmaceuticals' PB Ratio has ranged from 0.96 to 22.11. According to the industry distribution chart, SymBio Pharmaceuticals ranks #899 out of 921 companies in the Drug Manufacturers industry, placing it in the top 97.6%.
Is SymBio Pharmaceuticals' PB Ratio too high?
SymBio Pharmaceuticals' current PB Ratio of 21.80 is 644% above median its 10-year median of 2.93. Over the past 10 years, this metric has ranged from a low of 0.96 to a high of 22.11. The Drug Manufacturers industry median PB Ratio is 1.90. SymBio Pharmaceuticals' value of 21.80 is 1047.4% above this industry median. Based on the distribution chart, SymBio Pharmaceuticals ranks #899 out of 921 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, SymBio Pharmaceuticals has a GF Score™ of 35/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SymBio Pharmaceuticals' PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, SymBio Pharmaceuticals ranks #899 out of 921 companies for PB Ratio. This places SymBio Pharmaceuticals in the lower half of its industry. The industry median PB Ratio is 1.90. SymBio Pharmaceuticals' value of 21.80 is 1047.4% above this benchmark. Historically, SymBio Pharmaceuticals' own PB Ratio has ranged from 0.96 to 22.11 over the past decade. While the company's 10-year median is 2.93 vs. the industry median of 1.90, SymBio Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.90, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SymBio Pharmaceuticals's current PB Ratio of 21.80 is 1047.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on SymBio Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SymBio Pharmaceuticals's current PB Ratio is 21.80, which is 644% above median its own 10-year median of 2.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SymBio Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, SymBio Pharmaceuticals (TSE:4582) is currently considered Modestly Overvalued. The stock's GF Value™ is 円60.86, compared to a current price of 円70.00 — trading 15% above its estimated fair value. The current PB Ratio is 21.80, which is 644% above median its 10-year median of 2.93 and 1047.4% above the Drug Manufacturers industry median of 1.90. SymBio Pharmaceuticals' overall GF Score™ is 35/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For SymBio Pharmaceuticals (TSE:4582), the current PB Ratio is 21.80 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SymBio Pharmaceuticals (TSE:4582) Overvalued in 2026?
Based on GuruFocus' analysis, SymBio Pharmaceuticals stock appears to be overvalued.
The current stock price of 円70.00 is trading 15% above its estimated GF Value™ of 円60.86.
GuruFocus considers SymBio Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for TSE:4582:
PB Ratio: 21.80 (644% above median its 10-year median of 2.93)
GF Value™: 円60.86 vs. price of 円70.00 (15% above fair value)
Industry Position: 1047.4% above the Drug Manufacturers median (#899 of 921)
No single metric tells the full story. See the TSE:4582 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SymBio Pharmaceuticals Ltd is a biopharmaceutical company engaged in development of new drugs with a primary focus on the treatment of rare diseases, mainly in the areas of oncology, hematology and multiple viral infections, and conduct integrated business activities that encompass search for new drug candidates, development, manufacturing, and sales.
35GF Score
Get the complete analysis for TSE:4582
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4582 has been successfully added to your 
